These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 14500583)

  • 21. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value.
    Molina R; Augé JM; Escudero JM; Filella X; Zanon G; Pahisa J; Farrus B; Muñoz M; Velasco M
    Tumour Biol; 2010 Jun; 31(3):171-80. PubMed ID: 20361287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.
    Ali SM; Leitzel K; Chinchilli VM; Engle L; Demers L; Harvey HA; Carney W; Allard JW; Lipton A
    Clin Chem; 2002 Aug; 48(8):1314-20. PubMed ID: 12142389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
    Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
    Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.
    Yamauchi H; O'Neill A; Gelman R; Carney W; Tenney DY; Hösch S; Hayes DF
    J Clin Oncol; 1997 Jul; 15(7):2518-25. PubMed ID: 9215820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients.
    Thriveni K; Deshmane V; Bapsy PP; Krishnamoorthy L; Ramaswamy G
    Indian J Med Res; 2007 Feb; 125(2):137-42. PubMed ID: 17431282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
    Li Y; Peng Z; Zhang X; Gong J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
    Ross JS; Fletcher JA
    Stem Cells; 1998; 16(6):413-28. PubMed ID: 9831867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off?
    Badzek S; Kelovic VL; Plestina S; Humar I; Veir Z; Mihaljevic Z
    Wien Klin Wochenschr; 2011 Dec; 123(23-24):726-31. PubMed ID: 22113445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer.
    Aurilio G; Sandri MT; Pruneri G; Zorzino L; Botteri E; Munzone E; Adamoli L; Facchi G; Cullurà D; Verri E; Rocca MC; Zurrida S; Iacovelli R; Nolè F
    Future Oncol; 2016 Sep; 12(17):2001-8. PubMed ID: 27255717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
    Carney WP
    IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.
    Kim YS; Konoplev SN; Montemurro F; Hoy E; Smith TL; Rondón G; Champlin RE; Sahin AA; Ueno NT
    Clin Cancer Res; 2001 Dec; 7(12):4008-12. PubMed ID: 11751494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer.
    Christianson TA; Doherty JK; Lin YJ; Ramsey EE; Holmes R; Keenan EJ; Clinton GM
    Cancer Res; 1998 Nov; 58(22):5123-9. PubMed ID: 9823322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
    Singer CF; Köstler WJ; Hudelist G
    Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance and prognostic value of serum sHER-2/neu levels in patients with solid tumors.
    Papila C; Uzun H; Balci H; Zerdali H; Sezgin C; Can G; Yanardag H
    Med Oncol; 2009; 26(2):151-6. PubMed ID: 18855148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
    Sandri MT; Johansson H; Colleoni M; Zorzino L; Passerini R; Orlando L; Viale G
    Anticancer Res; 2004; 24(2C):1261-6. PubMed ID: 15154657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The extracellular domain of Her2 in serum as a biomarker of breast cancer.
    Perrier A; Gligorov J; Lefèvre G; Boissan M
    Lab Invest; 2018 Jun; 98(6):696-707. PubMed ID: 29491426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER-2/neu gene product in serum--an oncoprotein in the diagnosis and therapy of breast carcinoma.
    Schulze G
    Anticancer Res; 2003; 23(2A):1007-10. PubMed ID: 12820339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients.
    Leary AF; Hanna WM; van de Vijver MJ; Penault-Llorca F; Rüschoff J; Osamura RY; Bilous M; Dowsett M
    J Clin Oncol; 2009 Apr; 27(10):1694-705. PubMed ID: 19255333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.